Press releases
Access archived Guidant press releases
Access archived BTG press releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 1, 2004
(September 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) today provided an update on the sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for the month of August...
-
Aug 31, 2004
(August 31, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced six-month clinical findings from the European component of its Milestone II Registry. The Company said it has...
-
Aug 26, 2004
(August 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that enrollment has begun in its ATLAS clinical trial. ATLAS is the first trial using Boston Scientific's new Liberté™
-
Aug 25, 2004
(August 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast a conference call providing updates on its business performance for 2004 and sales of its TAXUS™ Express2™...
-
Aug 25, 2004
(August 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its Peripheral Cutting...
-
Aug 23, 2004
(August 23, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its FilterWire EZ Embolic...
-
Aug 19, 2004
(August 19, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved extending the shelf life of its TAXUS Express2...
-
Aug 10, 2004
(August 10, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has made a significant equity investment in Northstar Neuroscience, Inc., a privately held company located in...
-
Jul 26, 2004
(July 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for its second quarter ended June 30, 2004. Net sales for the second quarter were $1.460 billion as...
-
Jul 22, 2004
(July 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA) to begin its...
-
Jul 21, 2004
(July 21, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2004 on Monday, July 26, at 9:00...
-
Jul 16, 2004
(July 16, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it is expanding its voluntarily worldwide recall to include certain additional units of its TAXUS™ Express2™...
-
Jul 8, 2004
(July 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that enrollment has begun in its clinical trial known as FLAME. This prospective, multi-center, randomized study will...
-
Jul 2, 2004
(July 2, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it is voluntarily recalling nationwide approximately 200 units of its TAXUS™ Express2™ Paclitaxel-Eluting...
-
Jun 30, 2004
(June 30, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2004 on Monday, July 19, at 9:00...
-
Jun 25, 2004
(June 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today the completion of its public offering of $600 million aggregate principal amount of 5.45 percent Senior Notes due June...
-
Jun 22, 2004
(June 22, 2004) - Boston Scientific Corporation (NYSE: BSX) announced today the launch of a public offering of $500 million aggregate principal amount of senior notes, under the Company's existing...
-
Jun 8, 2004
(June 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in Goldman Sachs' 25th Annual Healthcare Conference, which is being held June 7-10 in Dana Point, CA. Larry...
-
Jun 3, 2004
(June 3, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for the...
-
Jun 1, 2004
and Valencia, California (June 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) and Advanced Bionics Corporation, a privately held company located in Valencia, CA, today announced the...
-
May 28, 2004
(May 28, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a decision by the U.S. District Court in Wilmington,...
-
May 26, 2004
and Paris (May 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced nine-month sub-population data from its TAXUS VI clinical trial. The trial enrolled 448 patients at 44 sites...
-
May 25, 2004
and Paris (May 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced nine-month results from its TAXUS VI clinical trial. The trial enrolled 448 patients at 44 sites in Europe,...
-
May 24, 2004
(May 24, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has completed enrollment in ARRIVE, a peri-approval registry. ARRIVE was designed to collect and analyze...
-
May 20, 2004
(May 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast an analyst meeting it is hosting on Wednesday, May 26, in conjunction with the Paris Course on Revascularization (PCR), the...
-
May 20, 2004
and New Orleans, LA (May 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced sub-population data from a 12-month, 117-patient study of the Enteryx procedure for patients...
-
May 18, 2004
and New Orleans, LA (May 18, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced clinical trial data supporting the safety and effectiveness of the Enteryx procedure in relieving...
-
May 17, 2004
(May 17, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Banc of America Securities Health Care Conference 2004, which is being held May 19-21 in Las Vegas....
-
May 4, 2004
(May 4, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for...
-
May 1, 2004
(May 18, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for...
-
Apr 30, 2004
(April 30, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Unplugged Conference, which is being held May 5-7 in Miami. On...
-
Apr 22, 2004
(April 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced 30-day safety data from its clinical trial to evaluate the benefits of stenting in conjunction with embolic protection...
-
Apr 20, 2004
(April 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for its first quarter ended March 31, 2004, as well as preliminary information related to U.S. sales...
-
Apr 19, 2004
(April 19, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Express® Biliary...
-
Apr 14, 2004
(April 14, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2004 on Tuesday, April 20, at 9:00...
-
Apr 8, 2004
(April 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced the U.S. launch of its Sentinol™ Self-Expanding Nitinol Biliary Stent System (Sentinol), which has been cleared by...
-
Apr 7, 2004
(April 7, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has acquired Precision Vascular Systems, Inc. (Precision Vascular), a privately held company located in West...
-
Apr 5, 2004
(April 5, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary results related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent system and...
-
Apr 1, 2004
(April 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the European Patent Office has declared invalid a patent held by Medinol Ltd. This is the patent that Boston...
-
Mar 31, 2004
(March 31, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has concluded enrollment in its TAXUS V de novo lesion clinical trial. The Company has enrolled 1,172...
-
Mar 29, 2004
(March 29, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Contour SE™...
-
Mar 25, 2004
(March 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) and EndoTex Interventional Systems, Inc. announced today the completion of enrollment in a carotid artery stenting clinical trial to...
-
Mar 22, 2004
(March 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent system....
-
Mar 10, 2004
(December 2, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it is voluntarily recalling all Stainless Steel Greenfield® Vena Cava Filters with 12Fr Femoral Introducer...
-
Mar 4, 2004
(March 4, 2004) - Boston Scientific Corporation (NYSE: BSX) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS™ Express2™...
-
Mar 4, 2004
(March 4, 2004) - Boston Scientific Corporation (NYSE: BSX) today announced that it has completed a land purchase in Kerkrade, the Netherlands. The site will house the Company's new distribution...
-
Feb 26, 2004
(February 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 7th Annual Lehman Brothers' 2004 Global Healthcare Conference, which is being held March 3-5 in...
-
Feb 23, 2004
and New York, NY (February 23, 2004) -- Boston Scientific Corporation (NYSE: BSX) today hosted a meeting with analysts and investors in New York and addressed growth prospects for the Company in...
-
Feb 20, 2004
(February 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has entered into an agreement with Guidant Corporation to settle all outstanding litigation between the two...